Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed May 7, 2020 · 10-Q · 37 days after period end · 0001731122-20-000447
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Net Income | -$7.24M | -$7.25M | -$4.75M | -$1.55M |
| EPS Diluted | -$0.12 | -$0.15 | -$0.11 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end
